<?xml version="1.0" encoding="UTF-8" standalone="yes"?><rss version="2.0">    <channel>        <title>GSK news</title>        <link>http://www.gsk.com/media/index.htm</link>        <description>GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news.</description>                    <item>                <title>GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020</title>                                    <description><![CDATA[GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020]]></description>                                <pubDate>Mon, 30 Jan 2012 10:24:27 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-875381.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-875381.htm</guid>                            </item>                    <item>                <title>GSK announces changes to the Board</title>                                    <description><![CDATA[GlaxoSmithKline plc today announced that at the company’s Annual General Meeting (AGM) in 2013, following nine years of respective service to the GSK Board, Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board.]]></description>                                <pubDate>Fri, 27 Jan 2012 11:07:11 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-871327.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-871327.htm</guid>                            </item>                    <item>                <title>GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina</title>                                    <description><![CDATA[GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina]]></description>                                <pubDate>Wed, 11 Jan 2012 12:29:01 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-844572.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-844572.htm</guid>                            </item>                    <item>                <title>GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily RelovairTM* in COPD and asthma</title>                                    <description><![CDATA[GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* (fluticasone furoate “FF”/vilanterol “VI”) in patients with chronic obstructive pulmonary disease (COPD) and of all but one of the pivotal studies in patients with asthma.]]></description>                                <pubDate>Mon, 09 Jan 2012 07:17:32 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-840683.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-840683.htm</guid>                            </item>                    <item>                <title>GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands</title>                                    <description><![CDATA[In February 2011 GSK announced its intention to divest non-core Consumer Healthcare OTC products predominantly in the United States and Europe with aggregate annual sales of approximately £500 million. The proposed divestment is designed to realise value for shareholders and simplify GSK’s Consumer Healthcare business and allow it to focus on its priority brands and markets.]]></description>                                <pubDate>Tue, 20 Dec 2011 13:32:07 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-821642.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-821642.htm</guid>                            </item>                    <item>                <title>GSK extends pneumococcal vaccine agreement with GAVI Alliance</title>                                    <description><![CDATA[GSK today announced it has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world‟s poorest countries from pneumococcal disease. Pneumococcal disease can lead to pneumonia, meningitis and sepsis and is a leading cause of death in children under the age of five in developing countries.]]></description>                                <pubDate>Fri, 16 Dec 2011 12:10:27 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-815404.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-815404.htm</guid>                            </item>                    <item>                <title>GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus</title>                                    <description><![CDATA[GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that dosing has been initiated in BLISS-SC, a new Phase III trial to evaluate the efficacy, safety and tolerability of BENLYSTA®  (belimumab) administered subcutaneously (SC) once-weekly to autoantibody-positive adults with active systemic lupus erythematosus (SLE).]]></description>                                <pubDate>Thu, 15 Dec 2011 12:59:41 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-813312.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-813312.htm</guid>                            </item>                    <item>                <title>GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium</title>                                    <description><![CDATA[Results from TEACH (Tykerb Evaluation After Chemotherapy) were presented today at the 2011 CRTC-AACR San Antonio Breast Cancer Symposium.]]></description>                                <pubDate>Thu, 08 Dec 2011 22:45:00 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-798637.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-798637.htm</guid>                            </item>                    <item>                <title>GSK and Help for Heroes partner to support the rehabilitation of wounded servicemen and women in the UK</title>                                    <description><![CDATA[GSK and Help for Heroes today announced a new partnership to help support injured British armed forces personnel successfully transition back into civilian life. The partnership will focus on the creation of a specialist 'Wellness Centre' at Tedworth House, a Personnel Recovery and Assessment Centre located in Wiltshire.]]></description>                                <pubDate>Wed, 07 Dec 2011 09:14:33 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-793122.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-793122.htm</guid>                            </item>                    <item>                <title>GSK statement in response to the Prime Minister’s speech on life sciences</title>                                    <description><![CDATA[“The Government’s strategy for Life Sciences is a very important next step on the journey to make the UK the best place in the world to locate pharmaceutical investment. The actions on research and manufacturing will further strengthen the attractiveness of the UK and most importantly the results of the Innovation Review should ensure that the NHS is a stronger adopter of innovative medicines and technology, ensuring that all patients can benefit from cost-effective treatments and interventions approved by NICE.]]></description>                                <pubDate>Mon, 05 Dec 2011 14:31:53 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-789508.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-789508.htm</guid>                            </item>            </channel></rss>
